Supplementary Material

Project ECHO: telementoring to educate and support prescribing of HIV pre-exposure prophylaxis by community medical providers

Brian R. Wood\textsuperscript{A,B,D}, Maren S. Mann\textsuperscript{C}, Natalia Martinez-Paz\textsuperscript{B}, Kenton T. Unruh\textsuperscript{B}, Mary Annese\textsuperscript{B}, David H. Spach\textsuperscript{A,B}, John D. Scott\textsuperscript{A} and Joanne D. Stekler\textsuperscript{A,B}

\textsuperscript{A}University of Washington Division of Allergy and Infectious Diseases, 1959 NE Pacific Street, Seattle, WA 98195, UA.

\textsuperscript{B}Mountain West AIDS Education and Training Center (MW AETC), 325 9th Avenue, Seattle, WA 98104, USA.

\textsuperscript{C}University of Washington School of Nursing, 1959 NE Pacific Street, Seattle, WA 98195, USA.

\textsuperscript{D}Corresponding author. Email: bwood2@uw.edu

Baseline Survey.

Follow-up Survey.
Baseline Survey

Pre-exposure prophylaxis (PrEP) is a strategy in which an HIV-uninfected person takes a medication daily to reduce the risk of HIV infection. The purpose of this survey is to learn about ECHO providers’ current familiarity with, and use of, PrEP as well as potential interest in education and support for prescribing PrEP.

1. Do you see the following categories of patients? (Check all that apply)
   - Men who have sex with men
   - Transgender women (male-to-female) and men (female-to-male)
   - Intravenous drug users
   - HIV-uninfected men or women whose partner is HIV-infected

2. What are your concerns about the use of PrEP as part of HIV prevention approaches (Check all that apply):
   - Effectiveness of PrEP
   - Not certain who PrEP is right for
   - Staff time involved
   - Cost to patients
   - Unreimbursed costs to our clinic
   - Adherence challenges
   - Drug resistance
   - Risk compensation (ie. decreased condom use)
   - Toxicity
   - Medication diversion (selling/sharing meds)
   - Other (please explain below):

3. Have you discussed PrEP with any of your patients? (whether or not you ended up prescribing it)
   - Yes
     If yes, with approximately how many patients? ___________________________
   - No

4. Have you prescribed PrEP for any of your patients?
   - Yes
     If yes, for approximately how many patients? ___________________________
     If yes, in approximately what proportion did you recommend PrEP? (versus the patient specifically asking for PrEP) _______________________
   - No
   - n/a
5. Which specific patient characteristics would prompt you to recommend PrEP (check all that apply)?

- □ MSM with history of condomless sex
- □ Man or woman with HIV-seropositive partner on ARV therapy
- □ Man or woman with HIV-seropositive partner not on ARV therapy
- □ Man or woman with recent STI
- □ Commercial sex worker
- □ Serodiscordant couple interested in conception
- □ Active injection drug user
- □ Other (please explain):

6. If one of your patients were interested in PrEP as part of their HIV prevention approach, how comfortable would you be in discussing and providing PrEP?

- Very uncomfortable □
- Somewhat uncomfortable □
- Neither comfortable nor uncomfortable □
- Somewhat comfortable □
- Very comfortable □

7. How comfortable do you feel talking with your patients about the following topics? (Check all that apply):

<table>
<thead>
<tr>
<th>Topic</th>
<th>Very comfortable</th>
<th>Somewhat comfortable</th>
<th>Somewhat uncomfortable</th>
<th>Very uncomfortable</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrEP candidacy</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Efficacy of PrEP</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Costs/insurance</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Risks/side effects</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Adherence</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Drug resistance</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Condoms/safe sex</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>HIV transmission risk</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
<tr>
<td>Monitoring on PrEP</td>
<td>□</td>
<td>□</td>
<td>□</td>
<td>□</td>
</tr>
</tbody>
</table>

8. What topics would you like to have discussed in the ECHO didactic sessions?

- Overview of PrEP efficacy □
- Assessing candidates for PrEP and baseline eval □
- Review of guidelines for prescribing PrEP □
- Insurance/financial resources □
- Adherence monitoring and support □
- HIV testing and other lab monitoring for PrEP patients □
- PrEP safety and drug resistance □
PEP to PrEP transition □
Other (please explain):

9. If an online tool were available to review PrEP data and prescribing guidelines and provide additional PrEP education and resources, how likely would you be to use it?

- Very likely □
- Somewhat likely □
- Neutral □
- Somewhat unlikely □
- Very unlikely □

THANKS. FEEL FREE TO WRITE ANY OTHER COMMENTS IN THE MARGINS!
Follow-up Survey

Thank you so much for participating in our survey. This survey is intended to evaluate the effectiveness of the ECHO sessions to provide education and support to you regarding HIV pre-exposure prophylaxis (PrEP). If you have any questions about this survey, please feel free to direct them towards Dr. Brian Wood (bwood2@uw.edu). Your answers to the following questions are confidential and will only be used within a larger data set as anonymous values. There are three parts to this survey, and should take less than 15 minutes of your time.

Name: ______________________________________________________________________

Unique AETC ID:

(HRSA requires a Unique ID [UID] for all trainees. If you do not have a UID already, you can create one by using the first 2 letters of your first and first 2 letters of your last name, followed by the 2-digit month and date of your birth. E.g.: Jane Smith, born 1/15 would be jasm0115)

Age:
- □ <30
- □ 30-39
- □ 40-49
- □ 50-59
- □ ≥60

Clinic location:
- □ Urban
- □ Suburban
- □ Rural

Clinic setting:
- □ Academic health center
- □ Hospital-based clinic
- □ Federally Qualified Health Center
- □ Rural Health Center
- □ Private Practice
- □ Other, please specify: ______________________________

What is your professional discipline?
- □ MD
- □ APRN
- □ PA
- □ PharmD
- □ Social Work
- □ Case Manager
- □ Registered Nurse
- □ Other, please specify:

Please specify the # of years you have been in practice:
Currently in training
☐ 0-5
☐ 6-10
☐ 11-20
☐ >20

Please specify the # of years you have been providing HIV care:
☐ Currently in training
☐ 0-5
☐ 6-10
☐ 11-20
☐ >20

How long have you been participating in the UW/MWAETC HIV ECHO sessions?
☐ <1 year
☐ 1-2 years
☐ 3-4 years
☐ >4 years

Have you participated in any ECHO session that included HIV PrEP in the form of either a PrEP-related didactic talk or PrEP as part of a case discussion?
☐ Yes
☐ No

If Yes, please continue.
If No, please STOP.

Part I: ECHO Sessions

1. To what degree has HIV ECHO (didactics or case discussions) addressed your concerns about the following HIV PrEP topics?

<table>
<thead>
<tr>
<th>Topic</th>
<th>Not at all</th>
<th>Slightly</th>
<th>Unsure</th>
<th>Moderately</th>
<th>Extremely</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adherence challenges</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost to patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Who PrEP is intended for</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk of drug Resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk Compensation (i.e. decreased condom use)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2. To what degree has ECHO increased your knowledge in each of the following specific areas of PrEP as part of HIV prevention?

<table>
<thead>
<tr>
<th></th>
<th>Not at all</th>
<th>Slightly</th>
<th>Unsure</th>
<th>Moderately</th>
<th>Extremely</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrEP candidacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline laboratory evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Insurance/Financial Resources</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lab monitoring</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supporting adherence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. Have you ever presented or observed a case during an ECHO session that included a discussion of any aspect of HIV PrEP?
   □ Presented
   □ Observed
   □ Both

**If you presented an HIV PrEP case during an ECHO session:**
Please now consider one case you presented and answer the following questions, giving as much detail as possible:

a. What was your main HIV PrEP question?

b. How much did presenting the case involving HIV PrEP influence your management of that case?
   □ not at all
   □ slightly
   □ unsure
   □ moderately
   □ extremely

c. Please describe how presenting the case impacted your management of that case:

d. How did presenting the case impact patient outcomes?

e. How would the patient outcome have been different without ECHO?

f. How much did presenting the case involving HIV PrEP influence your management of another patient/client in your practice?
   □ not at all
   □ slightly
If you observed an HIV PrEP case during an ECHO session (please complete even if you also presented a case):

a. How much did observing an HIV PrEP case presented during an ECHO session influence your management of patients/clients in your practice at risk for HIV acquisition?
   - not at all
   - slightly
   - unsure
   - moderately
   - extremely

Please give an example of a case in your practice that was influenced by knowledge gained from observing an HIV PrEP case or PrEP didactic during ECHO:

4. To what degree do you feel that participation in HIV ECHO has helped you stay up-to-date on HIV PrEP guidelines?
   - not at all
   - slightly
   - unsure
   - moderately
   - extremely

5. To what degree do you feel that participation in ECHO has increased your likelihood to offer HIV PrEP?
   - not at all
   - slightly
   - unsure
   - moderately
   - extremely

Why or why not?

Part II: Community:

6. Have you ever served as a resource to other providers in your area regarding HIV PrEP based on the knowledge you gained from ECHO participation?
   - Yes
   - No

7. If you did not participate in ECHO, would you be referring your patients/clients at risk for HIV to another provider for HIV PrEP?
   - Yes
   - No
8. Prior to ECHO, who were you turning to for clinical advice regarding HIV PrEP? (select all that apply)
   - Another provider at my practice setting
   - Another provider outside of my practice setting but not at the University of Washington
   - A provider at the University of Washington
   - The University of Washington MEDCON consultation and referral service
   - Another university consultation and referral service
   - AETC National Clinician Consultation Center/Pre-Exposure Prophylaxis Service (PrEPline)
   - None
   - Other, please specify:

**Part III: ECHO Participant and HIV PrEP**

9. Have you discussed HIV PrEP with any of your patients/clients?
   - Yes
   - No

   If yes, what percentage of those discussions were initiated by you (vs initiated by the patients/clients)?

10. How comfortable do you feel discussing HIV PrEP with your patients/clients?
    - very uncomfortable
    - somewhat uncomfortable
    - unsure
    - somewhat comfortable
    - very comfortable

11. How comfortable do you feel talking with your patients/clients about the following topics?

<table>
<thead>
<tr>
<th>Topic</th>
<th>Very Uncomfortable</th>
<th>Somewhat Uncomfortable</th>
<th>Unsure</th>
<th>Somewhat Comfortable</th>
<th>Very Comfortable</th>
</tr>
</thead>
<tbody>
<tr>
<td>PrEP candidacy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy of PrEP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Costs/Insurance coverage</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risks/Side Effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adherence</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Resistance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Condoms/Safe Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
12. Can/do you prescribe HIV PrEP?
   ☐ Yes
   ☐ No

13. If you are a prescriber, have you ever prescribed HIV PrEP for any of your patients/clients?
    ☐ Yes
    ☐ No

    If yes, for approximately how many patients/clients?

14. What concerns have prevented you from prescribing HIV PrEP? (select all that apply)
    ☐ Concern about adherence
    ☐ Concern about future resistance
    ☐ Cost/payer issues
    ☐ Concern about side effects
    ☐ Insufficient real-world evidence for HIV PrEP efficacy
    ☐ Other reasons, please specify:

15. What topics would you like to have discussed in future ECHO didactic sessions regarding HIV PrEP?

16. Would it be okay if we contact you either by email or phone in the future for a short conversation to gather more detail regarding your responses?
    ☐ Yes
    ☐ No

Thank you for your participation!

Sincerely,

The ECHO Team